Skip to main content

Table 3 Original data used for calculation

From: Efficacy and safety outcomes in novel oral anticoagulants versus vitamin-K antagonist on post-TAVI patients: a meta-analysis

Study

All-Cause Mortality

Bleeding

Disabling and nondiasbling stroke

Combined end-pointa

Stroke at early follow-up (30-day)

NOAC

VKA

NOAC

VKA

NOAC

VKA

NOAC

VKA

NOAC

VKA

Seeger et al., 2017 [26]

19 (81)

6 (50)

5 (81)

7 (50)

1 (81)

1 (50)

22 (81)

9 (50)

3 (141)

7 (131)

Geis et al., 2018 [27]

12 (154)

11 (172)

3 (154)

3 (172)

5 (154)

2 (172)

17 (154)

14 (172)

N/A

N/A

Jochheim et al., 2019 [28]

47 (326)

70 (636)

69 (326)

146 (636)

10 (326)

13 (636)

63 (326)

87 (636)

5 (326)

6 (636)

Butt et al., 2019 [29]

15 (99)

54 (357)

11 (94)

28 (343)

8 (93)

14 (346)

N/A

N/A

0 (213)

3 (516)

Kalogeras et al., 2019 [31]

13 (115)

16 (102)

6 (115)

9 (102)

N/A

N/A

N/A

N/A

N/A

N/A

Kosmidou et al., 2019 [30]

33 (155)

207 (778)

8 (155)

43 (778)

12 (155)

41 (778)

N/A

N/A

N/A

N/A

GALILEO, 2020 [32]

64 (826)

38 (818)

46 (826)

31 (818)

30 (826)

25 (818)

83 (826)

68 (818)

N/A

N/A

  1. aCombined end-points were defined as the composite of death from cardiovascular causes, stroke, myocardial infarction, symptomatic valve embolism, deep-vein thrombosis, or systemic embolism